SCHEMBL23364837

SCHEMBL23364837

CC(C)Oc1ccccc1-c1csc(N)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 3/20 0.53
HSD17B10 Q99714 2/20 0.53
ALDH1A1 P00352 6/20 0.46
ATP4A P20648 2/20 0.45
ATP4B P51164 2/20 0.45
KDM4E B2RXH2 3/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
RAB9A P51151 4/20 0.44
MAPT P10636 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
NPC1 O15118 2/20 0.44
CHRNA7 P36544 1/20 0.44
LMNA P02545 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP19A1 P11511 1/20 0.43
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29932883 1.00 MPL (0.53) MPLHSD17B10ALDH1A1ATP4AATP4B
SCHEMBL234658 0.82 ALDH1A1 (0.63) MPLHSD17B10ALDH1A1ATP4AATP4B
SCHEMBL29796690 0.82 ALDH1A1 (0.63) MPLHSD17B10ALDH1A1ATP4AATP4B
Iodide SCHEMBL11486465 0.81 ALDH1A1 (0.61) MPLHSD17B10ALDH1A1ATP4AATP4B
SCHEMBL29932728 0.79 MEN1 (0.45) MPLHSD17B10ALDH1A1KDM4EMEN1
SCHEMBL23364728 0.79 MEN1 (0.45) MPLHSD17B10ALDH1A1KDM4EMEN1
SCHEMBL29654054 0.76 CYP19A1 (0.66) MPLHSD17B10ALDH1A1ATP4AATP4B
SCHEMBL23364703 0.76 HSD17B10 (0.57) MPLHSD17B10ALDH1A1KDM4EMEN1
SCHEMBL29932854 0.76 HSD17B10 (0.57) MPLHSD17B10ALDH1A1KDM4EMEN1
SCHEMBL14726481 0.75 MPL (0.76) MPLHSD17B10ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION 2024-01-04 US disclosed
EP-4058439-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY Genzyme Corporation (US) 2022-09-21 EP disclosed
CN-115003659-A 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity 健赞公司 2022-09-02 CN disclosed
WO-2021097057-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION (US) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY CFTR, PKD2, PKD1 MPL 3017/4885HSD17B10 968/4885ALDH1A1 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.